Micro-X Begins Hospital Activation for First Human Head CT Stroke Imaging.
Micro-X Ltd (ASX: MX1) has moved closer to commercialising its portable Head CT technology after commencing activation of its first human trial site at the Royal Melbourne Hospital. The system is currently being installed and commissioned, positioning the hospital to become the first globally to undertake human imaging using Micro-X’s cold-cathode, carbon nanotube CT platform. Before patient scans begin, the company will complete a structured phantom imaging program, including image quality review by specialist neuroradiologists and neurologists, alongside detailed radiation dose analysis. The pilot study is intended to produce high-quality clinical data to underpin future regulatory pathways for stroke imaging applications. Alongside the Royal Melbourne Hospital rollout, Micro-X is assembling additional test systems to support trials at two further clinical sites. Development work is also advancing on an in-ambulance Head CT prototype, supported by Australian Government funding, reinforcing Micro-X’s ambition to enable faster stroke diagnosis by bringing CT imaging directly to patients.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Micro-X Begins Hospital Activation for First Human Head CT Stroke Imaging.
Micro-X Ltd (ASX: MX1) has moved closer to commercialising its portable Head CT technology after commencing activation of its first human trial site at the Royal Melbourne Hospital. The system is currently being installed and commissioned, positioning the hospital to become the first globally to undertake human imaging using Micro-X’s cold-cathode, carbon nanotube CT platform. Before patient scans begin, the company will complete a structured phantom imaging program, including image quality review by specialist neuroradiologists and neurologists, alongside detailed radiation dose analysis. The pilot study is intended to produce high-quality clinical data to underpin future regulatory pathways for stroke imaging applications. Alongside the Royal Melbourne Hospital rollout, Micro-X is assembling additional test systems to support trials at two further clinical sites. Development work is also advancing on an in-ambulance Head CT prototype, supported by Australian Government funding, reinforcing Micro-X’s ambition to enable faster stroke diagnosis by bringing CT imaging directly to patients.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au